SCHEMBL368924

SCHEMBL368924

CCn1cc(-n2ccc(=O)c(COc3ccc4ncc(-c5ccc(Cl)nc5)cc4c3)n2)cn1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 4/20 0.38
LRRK2 Q5S007 1/20 0.32
FGFR1 P11362 1/20 0.32
FGFR2 P21802 1/20 0.32
FGFR4 P22455 1/20 0.32
FGFR3 P22607 1/20 0.32
KDR P35968 1/20 0.32
TERT O14746 2/20 0.32
PDGFRB P09619 1/20 0.31
PDGFRA P16234 1/20 0.31
MET P08581 6/20 0.31
GRM5 P41594 1/20 0.31
PIK3CG P48736 2/20 0.31
PIK3CD O00329 1/20 0.31
PIK3CA P42336 1/20 0.31
PIK3CB P42338 1/20 0.31
PI4KA P42356 1/20 0.31
PI4KB Q9UBF8 1/20 0.31
PTGES O14684 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10283774 0.90 LRRK2 (0.36) LRRK2FGFR1FGFR2FGFR4FGFR3
SCHEMBL368322 0.90 PDGFRB (0.41) GRM2LRRK2FGFR1FGFR2FGFR4
SCHEMBL368139 0.89 PDGFRB (0.39) GRM2LRRK2FGFR1FGFR2FGFR4
SCHEMBL10283523 0.89 MET (0.39) LRRK2PDGFRBPDGFRAMETGRM5
SCHEMBL370955 0.89 MET (0.38) LRRK2PDGFRBPDGFRAMET
SCHEMBL14916103 0.89 GRIN2B (0.36) LRRK2FGFR1FGFR2FGFR4FGFR3
SCHEMBL371343 0.88 PDGFRB (0.45) GRM2LRRK2FGFR1FGFR2FGFR4
SCHEMBL359863 0.88 PDGFRB (0.34) GRM2LRRK2FGFR1FGFR2FGFR4
SCHEMBL14916575 0.87 GRIN1 (0.37) GRM2PDGFRBPDGFRAMET
SCHEMBL14915783 0.87 JAK2 (0.38) LRRK2PDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593107-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2013-05-22 EP claimed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US claimed
WO-2012009194-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO claimed
EP-2593107-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2013-05-22 EP disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
WO-2012009194-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO disclosed
WO-2012009194-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116231-A1 TYROSINE KINASE INHIBITORS ABL1, ERBB2, MET GRM2 696/4885LRRK2 510/4885FGFR1 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.